NR4A1 and breast cancer: Triple-negative breast cancer accounts for over 15–20% of all breast cancers and, by being negative for hormone receptors, becomes therapeutically challenging due to its low response to treatment and highly invasive nature, resulting in a worse prognosis for affected patients [31,43].